LONDON and SALT LAKE CITY, July
23, 2019 /PRNewswire/ -- Hikma Pharmaceuticals
PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(rated Ba1 Moody's / BB+ S&P, both stable), the
multinational generic pharmaceutical company and Civica Rx (Civica,
Inc.) today announce a five-year agreement to manufacture and
supply Civica's growing membership of US health systems with
medications that are often in short supply in US hospitals.
Under the agreement, Hikma will produce 14 essential sterile
injectable medications for Civica as a private label distributor,
using Hikma's Abbreviated New Drug Applications (ANDAs) and
Civica's labeling and National Drug Code (NDC). These medicines are
used daily by hospitals in emergency care, surgery, pain management
and in treating hypertension. The list of products included in the
agreement will be publicly announced in the near future, and
initial shipments are expected to begin before the end of 2019.
Civica was founded in 2018 by leading US hospital systems
concerned about generic drug shortages and philanthropic
organizations passionate about improving healthcare. To date, more
than 30 health systems are Civica members, representing more than
900 US hospitals and approximately 30 percent of all licensed US
hospital beds.
Hikma is the third largest US supplier of generic injectable
medicines with a growing portfolio of more than 100 injectable
products. Today, one in every six generic injectable medicines used
in US hospitals is a Hikma product. During the last three years,
Hikma has launched more than 20 medications into US shortage
situations and in 2016 the company received a Drug Shortage
Assistance Award from the US Food and Drug Administration (FDA) for
its role in preventing or alleviating drug shortages.
"Hikma is thrilled to be partnering with Civica to reduce drug
shortages, and we share their commitment to providing hospitals and
doctors with a steady and reliable supply of high-quality
injectable medicines needed for successful patient care," said
Daniel Motto, Hikma's EVP of
Commercial & Business Development, US Injectables. "This
agreement recognizes both our ability to deliver a large and
consistent supply of quality medicines, and the significant
investments we have made to expand our injectable manufacturing
capacity and capabilities."
"We applaud Hikma's clear commitment to reducing drug
shortages," said Martin VanTrieste,
President and CEO of Civica Rx. "Our partnership will help us make
an impact as quickly as possible. We specifically chose Hikma
because of their strong manufacturing capabilities and believe
their excellent quality and supply record will be key to our
success in ensuring vital medications are consistently available
for hospitals and patients who need them."
"We are privileged to be working with Civica and we appreciate
their five-year commitment to guaranteed demand and fair and
sustainable pricing, which supports more effective production
planning and long-term investments in manufacturing," said Riad
Mishlawi, President, Hikma Injectables. "We believe Hikma's size
and scale, broad portfolio of medicines and robust pipeline across
growing therapeutic areas will enable us to build on this
partnership in the future. We are committed to working with Civica
and all of our customers as a reliable partner, capable of serving
the growing needs of US hospitals and clinics for a wide-range of
essential medicines."
About Civica Rx
Civica was established in 2018 to
reduce chronic generic drug shortages in the US and exists in the
public interest as a non-profit, non-stock corporation committed to
stabilizing the supply of essential generic medications in a
hospital setting. Civica's membership includes a Governing Board
and Founding and Partnering Members.
Civica will act in the best interest of patients to eliminate
uncertainty in the generic drug supply chain through long-term
contracts with health system members as well as its manufacturing
partners. Civica is committed to transparency and will offer fair
and sustainable prices to its member hospitals. It will also ensure
it has dedicated manufacturing capacity for the medications that
are most desperately needed in hospitals across the country through
redundant manufacturing and strategic stockpiling of medications to
prevent drug shortages in the future.
Civica aims to stabilize the supply of antibiotics, anesthetics,
cardiac medications, pain management medications, and other
essential sterile injectable medicines used in hospitals daily. It
is actively pursuing a three-pronged product supply
strategy:
- Working with multiple generic drug manufacturers that have the
US FDA approved manufacturing facilities and capacity to produce
Civica labeled generic drugs, allowing manufacturers to re-enter
the market or increase existing capacity
- Developing and acquiring Abbreviated New Drug Applications
(ANDAs) for generic drugs and working with contract manufacturing
organizations to produce Civica medications
- Acquiring and building Civica manufacturing facilities using
Civica's ANDAs
More information about Civica can be found
at www.civicarx.org and https://civicarx.org/media/.
About Hikma
Hikma helps put better health within reach
every day for millions of people in more than 50 countries around
the world. For more than 40 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
We are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and
expertise to transform cutting-edge science into innovative
solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively
and acting practically, we provide them with a broad range of
branded and non-branded generic medicines. Together, our 8,400
colleagues are helping to shape a healthier world that enriches all
our communities. We are a leading licensing partner in the MENA
region, and through our venture capital arm, are helping bring
innovative health technologies to people around the world. For more
information, please visit: www.hikma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hikma-and-civica-rx-sign-long-term-agreement-to-reduce-generic-drug-shortages-in-the-us-300889068.html
SOURCE Hikma; Civica Rx